Last reviewed · How we verify
Bifonazole spray once daily
Bifonazole is an antifungal agent that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.
Bifonazole is an antifungal agent that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. Used for Cutaneous candidiasis, Dermatophytosis.
At a glance
| Generic name | Bifonazole spray once daily |
|---|---|
| Sponsor | Bayer |
| Drug class | azole antifungal |
| Target | lanosterol 14α-demethylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Bifonazole achieves this by targeting the enzyme lanosterol 14α-demethylase, which is necessary for the conversion of lanosterol to ergosterol. This disruption of ergosterol synthesis ultimately leads to the death of fungal cells. Bifonazole is effective against a wide range of fungal pathogens, including dermatophytes, yeasts, and molds.
Approved indications
- Cutaneous candidiasis
- Dermatophytosis
Common side effects
- Skin irritation
- Allergic reactions
Key clinical trials
- Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bifonazole spray once daily CI brief — competitive landscape report
- Bifonazole spray once daily updates RSS · CI watch RSS
- Bayer portfolio CI